Efavirenz News and Research

RSS
Efavirenz, also known as EFV or Sustiva, is a type of medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Efavirenz was approved by the FDA on September 17, 1998, for use with other antiretroviral agents in the treatment of HIV infection in adults and children ages 3 and older. This medicine does not cure HIV infection or AIDS and does not reduce the risk of passing the virus to other people. Efavirenz may also be used with other antiretroviral medications to prevent HIV in people who have been exposed to the virus in the work place, such as health care providers who come in contact with HIV infected blood through an accidental needle stick.
Study reveals potential strength of different anti-HIV combination drugs

Study reveals potential strength of different anti-HIV combination drugs

Study explores links between antiretroviral prophylaxis, cleft lip and palate

Study explores links between antiretroviral prophylaxis, cleft lip and palate

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

Gilead submits Quad NDA to FDA for treatment of HIV-1 infection

Gilead submits Quad NDA to FDA for treatment of HIV-1 infection

Merck announces results from ISENTRESS Phase III combination study on HIV-1

Merck announces results from ISENTRESS Phase III combination study on HIV-1

Gilead announces EMA CHMP positive opinion for HIV-1 drug, Eviplera

Gilead announces EMA CHMP positive opinion for HIV-1 drug, Eviplera

Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapy

Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapy

Gilead’s Quad Phase 3 clinical study in treatment-naïve HIV-1 patients meets 48-week primary objective

Gilead’s Quad Phase 3 clinical study in treatment-naïve HIV-1 patients meets 48-week primary objective

FDA approves Gilead's Complera for treatment of HIV-1 infection

FDA approves Gilead's Complera for treatment of HIV-1 infection

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

Lancet issue dedicated to HIV/AIDS ahead of IAS conference

Lancet issue dedicated to HIV/AIDS ahead of IAS conference

AIDS activists and advocates to protest against Gilead's drug pricing at San Francisco federal building

AIDS activists and advocates to protest against Gilead's drug pricing at San Francisco federal building

Tobira commences cenicriviroc Phase IIb clinical trial for HIV infection

Tobira commences cenicriviroc Phase IIb clinical trial for HIV infection

Edurant receives FDA approval for treatment of HIV-1 infection

Edurant receives FDA approval for treatment of HIV-1 infection

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck announces initial results from ISENTRESS Phase III study in HIV-1